Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Connection

Co-Authors

This is a "connection" page, showing publications co-authored by David Siegel and David Ross.

 
Connection Strength
 
 
 
12.328
 
  1. Ross D, Siegel D. The diverse functionality of NQO1 and its roles in redox control. Redox Biol. 2021 May; 41:101950.
    View in: PubMed
    Score: 0.982
  2. Siegel D, Bersie S, Harris P, Di Francesco A, Armstrong M, Reisdorph N, Bernier M, de Cabo R, Fritz K, Ross D. A redox-mediated conformational change in NQO1 controls binding to microtubules and a-tubulin acetylation. Redox Biol. 2021 02; 39:101840.
    View in: PubMed
    Score: 0.965
  3. Siegel D, Baca SM, Thompson DC, Huntsman MM, Mower MM, Ross D. The effect of anodal/cathodal biphasic electrical stimulation on insulin release. J Cell Physiol. 2019 Feb 11.
    View in: PubMed
    Score: 0.849
  4. Siegel D, Dehn DD, Bokatzian SS, Quinn K, Backos DS, Di Francesco A, Bernier M, Reisdorph N, de Cabo R, Ross D. Redox modulation of NQO1. PLoS One. 2018; 13(1):e0190717.
    View in: PubMed
    Score: 0.786
  5. Ross D, Siegel D. Functions of NQO1 in Cellular Protection and CoQ10 Metabolism and its Potential Role as a Redox Sensitive Molecular Switch. Front Physiol. 2017; 8:595.
    View in: PubMed
    Score: 0.767
  6. Siegel D, Kepa JK, Ross D. NAD(P)H:quinone oxidoreductase 1 (NQO1) localizes to the mitotic spindle in human cells. PLoS One. 2012; 7(9):e44861.
    View in: PubMed
    Score: 0.544
  7. Siegel D, Yan C, Ross D. NAD(P)H:quinone oxidoreductase 1 (NQO1) in the sensitivity and resistance to antitumor quinones. Biochem Pharmacol. 2012 Apr 15; 83(8):1033-40.
    View in: PubMed
    Score: 0.518
  8. Siegel D, Shieh B, Yan C, Kepa JK, Ross D. Role for NAD(P)H:quinone oxidoreductase 1 and manganese-dependent superoxide dismutase in 17-(allylamino)-17-demethoxygeldanamycin-induced heat shock protein 90 inhibition in pancreatic cancer cells. J Pharmacol Exp Ther. 2011 Mar; 336(3):874-80.
    View in: PubMed
    Score: 0.482
  9. Ross D, Zhou H, Siegel D. Benzene toxicity: The role of the susceptibility factor NQO1 in bone marrow endothelial cell signaling and function. Chem Biol Interact. 2011 Jun 30; 192(1-2):145-9.
    View in: PubMed
    Score: 0.477
  10. Siegel D, Kepa JK, Ross D. Biochemical and genetic analysis of NAD(P)H:quinone oxidoreductase 1 (NQO1). Curr Protoc Toxicol. 2007; Chapter 4:Unit4.22.
    View in: PubMed
    Score: 0.367
  11. Siegel D, Gustafson DL, Dehn DL, Han JY, Boonchoong P, Berliner LJ, Ross D. NAD(P)H:quinone oxidoreductase 1: role as a superoxide scavenger. Mol Pharmacol. 2004 May; 65(5):1238-47.
    View in: PubMed
    Score: 0.305
  12. Ross D, Siegel D. NAD(P)H:quinone oxidoreductase 1 (NQO1, DT-diaphorase), functions and pharmacogenetics. Methods Enzymol. 2004; 382:115-44.
    View in: PubMed
    Score: 0.298
  13. Siegel D, Ryder J, Ross D. NAD(P)H: quinone oxidoreductase 1 expression in human bone marrow endothelial cells. Toxicol Lett. 2001 Dec 15; 125(1-3):93-8.
    View in: PubMed
    Score: 0.258
  14. Siegel D, Anwar A, Winski SL, Kepa JK, Zolman KL, Ross D. Rapid polyubiquitination and proteasomal degradation of a mutant form of NAD(P)H:quinone oxidoreductase 1. Mol Pharmacol. 2001 Feb; 59(2):263-8.
    View in: PubMed
    Score: 0.243
  15. Ross D, Kepa JK, Winski SL, Beall HD, Anwar A, Siegel D. NAD(P)H:quinone oxidoreductase 1 (NQO1): chemoprotection, bioactivation, gene regulation and genetic polymorphisms. Chem Biol Interact. 2000 Dec 01; 129(1-2):77-97.
    View in: PubMed
    Score: 0.241
  16. Siegel D, Ross D. Immunodetection of NAD(P)H:quinone oxidoreductase 1 (NQO1) in human tissues. Free Radic Biol Med. 2000 Aug; 29(3-4):246-53.
    View in: PubMed
    Score: 0.235
  17. Siegel D, McGuinness SM, Winski SL, Ross D. Genotype-phenotype relationships in studies of a polymorphism in NAD(P)H:quinone oxidoreductase 1. Pharmacogenetics. 1999 Feb; 9(1):113-21.
    View in: PubMed
    Score: 0.212
  18. Siegel D, Franklin WA, Ross D. Immunohistochemical detection of NAD(P)H:quinone oxidoreductase in human lung and lung tumors. Clin Cancer Res. 1998 Sep; 4(9):2065-70.
    View in: PubMed
    Score: 0.206
  19. Siegel D, Bolton EM, Burr JA, Liebler DC, Ross D. The reduction of alpha-tocopherolquinone by human NAD(P)H: quinone oxidoreductase: the role of alpha-tocopherolhydroquinone as a cellular antioxidant. Mol Pharmacol. 1997 Aug; 52(2):300-5.
    View in: PubMed
    Score: 0.191
  20. Xiong R, Zhou W, Siegel D, Kitson RR, Freed CR, Moody CJ, Ross D. A Novel Hsp90 Inhibitor Activates Compensatory Heat Shock Protein Responses and Autophagy and Alleviates Mutant A53T a-Synuclein Toxicity. Mol Pharmacol. 2015 Dec; 88(6):1045-54.
    View in: PubMed
    Score: 0.168
  21. Xiong R, Siegel D, Ross D. Quinone-induced protein handling changes: implications for major protein handling systems in quinone-mediated toxicity. Toxicol Appl Pharmacol. 2014 Oct 15; 280(2):285-95.
    View in: PubMed
    Score: 0.156
  22. Chang CH, Drechsel DA, Kitson RR, Siegel D, You Q, Backos DS, Ju C, Moody CJ, Ross D. 19-substituted benzoquinone ansamycin heat shock protein-90 inhibitors: biological activity and decreased off-target toxicity. Mol Pharmacol. 2014 Jun; 85(6):849-57.
    View in: PubMed
    Score: 0.151
  23. Xiong R, Siegel D, Ross D. The activation sequence of cellular protein handling systems after proteasomal inhibition in dopaminergic cells. Chem Biol Interact. 2013 Jul 05; 204(2):116-24.
    View in: PubMed
    Score: 0.143
  24. Yan C, Siegel D, Newsome J, Chilloux A, Moody CJ, Ross D. Antitumor indolequinones induced apoptosis in human pancreatic cancer cells via inhibition of thioredoxin reductase and activation of redox signaling. Mol Pharmacol. 2012 Mar; 81(3):401-10.
    View in: PubMed
    Score: 0.129
  25. Yan C, Dufour M, Siegel D, Reigan P, Gomez J, Shieh B, Moody CJ, Ross D. Indolequinone inhibitors of NRH:quinone oxidoreductase 2. Characterization of the mechanism of inhibition in both cell-free and cellular systems. Biochemistry. 2011 Aug 09; 50(31):6678-88.
    View in: PubMed
    Score: 0.126
  26. Reigan P, Siegel D, Guo W, Ross D. A mechanistic and structural analysis of the inhibition of the 90-kDa heat shock protein by the benzoquinone and hydroquinone ansamycins. Mol Pharmacol. 2011 May; 79(5):823-32.
    View in: PubMed
    Score: 0.122
  27. Zhou H, Dehn D, Kepa JK, Siegel D, Scott DE, Tan W, Ross D. NAD(P)H:quinone oxidoreductase 1-compromised human bone marrow endothelial cells exhibit decreased adhesion molecule expression and CD34+ hematopoietic cell adhesion. J Pharmacol Exp Ther. 2010 Jul; 334(1):260-8.
    View in: PubMed
    Score: 0.115
  28. Zhou H, Kepa JK, Siegel D, Miura S, Hiraki Y, Ross D. Benzene metabolite hydroquinone up-regulates chondromodulin-I and inhibits tube formation in human bone marrow endothelial cells. Mol Pharmacol. 2009 Sep; 76(3):579-87.
    View in: PubMed
    Score: 0.109
  29. Yan C, Shieh B, Reigan P, Zhang Z, Colucci MA, Chilloux A, Newsome JJ, Siegel D, Chan D, Moody CJ, Ross D. Potent activity of indolequinones against human pancreatic cancer: identification of thioredoxin reductase as a potential target. Mol Pharmacol. 2009 Jul; 76(1):163-72.
    View in: PubMed
    Score: 0.107
  30. Guo W, Siegel D, Ross D. Stability of the Hsp90 inhibitor 17AAG hydroquinone and prevention of metal-catalyzed oxidation. J Pharm Sci. 2008 Dec; 97(12):5147-57.
    View in: PubMed
    Score: 0.105
  31. Yan C, Kepa JK, Siegel D, Stratford IJ, Ross D. Dissecting the role of multiple reductases in bioactivation and cytotoxicity of the antitumor agent 2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone (RH1). Mol Pharmacol. 2008 Dec; 74(6):1657-65.
    View in: PubMed
    Score: 0.103
  32. Guo W, Reigan P, Siegel D, Ross D. Enzymatic reduction and glutathione conjugation of benzoquinone ansamycin heat shock protein 90 inhibitors: relevance for toxicity and mechanism of action. Drug Metab Dispos. 2008 Oct; 36(10):2050-7.
    View in: PubMed
    Score: 0.102
  33. Reigan P, Colucci MA, Siegel D, Chilloux A, Moody CJ, Ross D. Development of indolequinone mechanism-based inhibitors of NAD(P)H:quinone oxidoreductase 1 (NQO1): NQO1 inhibition and growth inhibitory activity in human pancreatic MIA PaCa-2 cancer cells. Biochemistry. 2007 May 22; 46(20):5941-50.
    View in: PubMed
    Score: 0.094
  34. Guo W, Reigan P, Siegel D, Zirrolli J, Gustafson D, Ross D. The bioreduction of a series of benzoquinone ansamycins by NAD(P)H:quinone oxidoreductase 1 to more potent heat shock protein 90 inhibitors, the hydroquinone ansamycins. Mol Pharmacol. 2006 Oct; 70(4):1194-203.
    View in: PubMed
    Score: 0.089
  35. Dehn DL, Siegel D, Zafar KS, Reigan P, Swann E, Moody CJ, Ross D. 5-Methoxy-1,2-dimethyl-3-[(4-nitrophenoxy)methyl]indole-4,7-dione, a mechanism-based inhibitor of NAD(P)H:quinone oxidoreductase 1, exhibits activity against human pancreatic cancer in vitro and in vivo. . 2006 Jul; 5(7):1702-9.
    View in: PubMed
    Score: 0.089
  36. Zafar KS, Siegel D, Ross D. A potential role for cyclized quinones derived from dopamine, DOPA, and 3,4-dihydroxyphenylacetic acid in proteasomal inhibition. Mol Pharmacol. 2006 Sep; 70(3):1079-86.
    View in: PubMed
    Score: 0.088
  37. Guo W, Reigan P, Siegel D, Zirrolli J, Gustafson D, Ross D. Formation of 17-allylamino-demethoxygeldanamycin (17-AAG) hydroquinone by NAD(P)H:quinone oxidoreductase 1: role of 17-AAG hydroquinone in heat shock protein 90 inhibition. Cancer Res. 2005 Nov 01; 65(21):10006-15.
    View in: PubMed
    Score: 0.085
  38. Bironaite D, Siegel D, Moran JL, Weksler BB, Ross D. Stimulation of endothelial IL-8 (eIL-8) production and apoptosis by phenolic metabolites of benzene in HL-60 cells and human bone marrow endothelial cells. Chem Biol Interact. 2004 Oct 15; 149(2-3):177-88.
    View in: PubMed
    Score: 0.079
  39. Bironaite D, Siegel D, Moran JL, Weksler BB, Ross D. Stimulation of endothelial IL-8 (eIL-8) production and apoptosis by phenolic metabolites of benzene in HL-60 cells and human bone marrow endothelial cells. Chem Biol Interact. 2004 Aug 10; 149(1):37-49.
    View in: PubMed
    Score: 0.078
  40. Dehn DL, Siegel D, Swann E, Moody CJ, Ross D. Biochemical, cytotoxic, and genotoxic effects of ES936, a mechanism-based inhibitor of NAD(P)H:quinone oxidoreductase 1, in cellular systems. Mol Pharmacol. 2003 Sep; 64(3):714-20.
    View in: PubMed
    Score: 0.073
  41. Anwar A, Dehn D, Siegel D, Kepa JK, Tang LJ, Pietenpol JA, Ross D. Interaction of human NAD(P)H:quinone oxidoreductase 1 (NQO1) with the tumor suppressor protein p53 in cells and cell-free systems. J Biol Chem. 2003 Mar 21; 278(12):10368-73.
    View in: PubMed
    Score: 0.070
  42. Anwar A, Siegel D, Kepa JK, Ross D. Interaction of the molecular chaperone Hsp70 with human NAD(P)H:quinone oxidoreductase 1. J Biol Chem. 2002 Apr 19; 277(16):14060-7.
    View in: PubMed
    Score: 0.065
  43. Winski SL, Faig M, Bianchet MA, Siegel D, Swann E, Fung K, Duncan MW, Moody CJ, Amzel LM, Ross D. Characterization of a mechanism-based inhibitor of NAD(P)H:quinone oxidoreductase 1 by biochemical, X-ray crystallographic, and mass spectrometric approaches. Biochemistry. 2001 Dec 18; 40(50):15135-42.
    View in: PubMed
    Score: 0.065
  44. Wilson MW, Schelonka LP, Siegel D, Meininger A, Ross D. Immunohistochemical localization of NAD(P)H:quinone oxidoreductase in conjunctival melanomas and primary acquired melanosis. Curr Eye Res. 2001 May; 22(5):348-52.
    View in: PubMed
    Score: 0.062
  45. Di Francesco A, Choi Y, Bernier M, Zhang Y, Diaz-Ruiz A, Aon MA, Kalafut K, Ehrlich MR, Murt K, Ali A, Pearson KJ, Levan S, Preston JD, Martin-Montalvo A, Martindale JL, Abdelmohsen K, Michel CR, Willmes DM, Henke C, Navas P, Villalba JM, Siegel D, Gorospe M, Fritz K, Biswal S, Ross D, de Cabo R. NQO1 protects obese mice through improvements in glucose and lipid metabolism. NPJ Aging Mech Dis. 2020 Nov 19; 6(1):13.
    View in: PubMed
    Score: 0.060
  46. Schelonka LP, Siegel D, Wilson MW, Meininger A, Ross D. Immunohistochemical localization of NQO1 in epithelial dysplasia and neoplasia and in donor eyes. Invest Ophthalmol Vis Sci. 2000 Jun; 41(7):1617-22.
    View in: PubMed
    Score: 0.058
  47. Moran JL, Siegel D, Ross D. A potential mechanism underlying the increased susceptibility of individuals with a polymorphism in NAD(P)H:quinone oxidoreductase 1 (NQO1) to benzene toxicity. Proc Natl Acad Sci U S A. 1999 Jul 06; 96(14):8150-5.
    View in: PubMed
    Score: 0.055
  48. Traver RD, Siegel D, Beall HD, Phillips RM, Gibson NW, Franklin WA, Ross D. Characterization of a polymorphism in NAD(P)H: quinone oxidoreductase (DT-diaphorase). Br J Cancer. 1997; 75(1):69-75.
    View in: PubMed
    Score: 0.046
  49. Ross D, Siegel D, Schattenberg DG, Sun XM, Moran JL. Cell-specific activation and detoxification of benzene metabolites in mouse and human bone marrow: identification of target cells and a potential role for modulation of apoptosis in benzene toxicity. Environ Health Perspect. 1996 Dec; 104 Suppl 6:1177-82.
    View in: PubMed
    Score: 0.046
  50. Moran JL, Siegel D, Sun XM, Ross D. Induction of apoptosis by benzene metabolites in HL60 and CD34+ human bone marrow progenitor cells. Mol Pharmacol. 1996 Sep; 50(3):610-5.
    View in: PubMed
    Score: 0.045
  51. Di Francesco A, Di Germanio C, Panda AC, Huynh P, Peaden R, Navas-Enamorado I, Bastian P, Lehrmann E, Diaz-Ruiz A, Ross D, Siegel D, Martindale JL, Bernier M, Gorospe M, Abdelmohsen K, de Cabo R. Novel RNA-binding activity of NQO1 promotes SERPINA1 mRNA translation. Free Radic Biol Med. 2016 10; 99:225-233.
    View in: PubMed
    Score: 0.045
  52. Blunt CE, Torcuk C, Liu Y, Lewis W, Siegel D, Ross D, Moody CJ. Synthesis and Intracellular Redox Cycling of Natural Quinones and Their Analogues and Identification of Indoleamine-2,3-dioxygenase (IDO) as Potential Target for Anticancer Activity. Angew Chem Int Ed Engl. 2015 Jul 20; 54(30):8740-5.
    View in: PubMed
    Score: 0.041
  53. Inman M, Visconti A, Yan C, Siegel D, Ross D, Moody CJ. Antitumour indolequinones: synthesis and activity against human pancreatic cancer cells. Org Biomol Chem. 2014 Jul 21; 12(27):4848-61.
    View in: PubMed
    Score: 0.039
  54. Carvalho C, Siegel D, Inman M, Xiong R, Ross D, Moody CJ. Benzofuranquinones as inhibitors of indoleamine 2,3-dioxygenase (IDO). Synthesis and biological evaluation. Org Biomol Chem. 2014 May 07; 12(17):2663-74.
    View in: PubMed
    Score: 0.038
  55. Pasceri R, Siegel D, Ross D, Moody CJ. Aminophenoxazinones as inhibitors of indoleamine 2,3-dioxygenase (IDO). Synthesis of exfoliazone and chandrananimycin A. J Med Chem. 2013 Apr 25; 56(8):3310-7.
    View in: PubMed
    Score: 0.035
  56. Kitson RR, Chang CH, Xiong R, Williams HE, Davis AL, Lewis W, Dehn DL, Siegel D, Roe SM, Prodromou C, Ross D, Moody CJ. Synthesis of 19-substituted geldanamycins with altered conformations and their binding to heat shock protein Hsp90. Nat Chem. 2013 Apr; 5(4):307-14.
    View in: PubMed
    Score: 0.035
  57. Dufour M, Yan C, Siegel D, Colucci MA, Jenner M, Oldham NJ, Gomez J, Reigan P, Li Y, De Matteis CI, Ross D, Moody CJ. Mechanism-based inhibition of quinone reductase 2 (NQO2): selectivity for NQO2 over NQO1 and structural basis for flavoprotein inhibition. Chembiochem. 2011 May 16; 12(8):1203-8.
    View in: PubMed
    Score: 0.031
  58. Chan KM, Rajab NF, Siegel D, Din LB, Ross D, Inayat-Hussain SH. Goniothalamin induces coronary artery smooth muscle cells apoptosis: the p53-dependent caspase-2 activation pathway. Toxicol Sci. 2010 Aug; 116(2):533-48.
    View in: PubMed
    Score: 0.029
  59. Thomas DJ, Sadler A, Subrahmanyam VV, Siegel D, Reasor MJ, Wierda D, Ross D. Bone marrow stromal cell bioactivation and detoxification of the benzene metabolite hydroquinone: comparison of macrophages and fibroblastoid cells. Mol Pharmacol. 1990 Feb; 37(2):255-62.
    View in: PubMed
    Score: 0.028
  60. Ross D, Siegel D, Gibson NW, Pacheco D, Thomas DJ, Reasor M, Wierda D. Activation and deactivation of quinones catalyzed by DT-diaphorase. Evidence for bioreductive activation of diaziquone (AZQ) in human tumor cells and detoxification of benzene metabolites in bone marrow stroma. Free Radic Res Commun. 1990; 8(4-6):373-81.
    View in: PubMed
    Score: 0.028
  61. Nolan KA, Doncaster JR, Dunstan MS, Scott KA, Frenkel AD, Siegel D, Ross D, Barnes J, Levy C, Leys D, Whitehead RC, Stratford IJ, Bryce RA. Synthesis and biological evaluation of coumarin-based inhibitors of NAD(P)H: quinone oxidoreductase-1 (NQO1). J Med Chem. 2009 Nov 26; 52(22):7142-56.
    View in: PubMed
    Score: 0.028
  62. Nolan KA, Zhao H, Faulder PF, Frenkel AD, Timson DJ, Siegel D, Ross D, Burke TR, Stratford IJ, Bryce RA. Coumarin-based inhibitors of human NAD(P)H:quinone oxidoreductase-1. Identification, structure-activity, off-target effects and in vitro human pancreatic cancer toxicity. J Med Chem. 2007 Dec 13; 50(25):6316-25.
    View in: PubMed
    Score: 0.024
  63. Colucci MA, Reigan P, Siegel D, Chilloux A, Ross D, Moody CJ. Synthesis and evaluation of 3-aryloxymethyl-1,2-dimethylindole-4,7-diones as mechanism-based inhibitors of NAD(P)H:quinone oxidoreductase 1 (NQO1) activity. J Med Chem. 2007 Nov 15; 50(23):5780-9.
    View in: PubMed
    Score: 0.024
  64. van Muiswinkel FL, de Vos RA, Bol JG, Andringa G, Jansen Steur EN, Ross D, Siegel D, Drukarch B. Expression of NAD(P)H:quinone oxidoreductase in the normal and Parkinsonian substantia nigra. Neurobiol Aging. 2004 Oct; 25(9):1253-62.
    View in: PubMed
    Score: 0.020
  65. Sarbia M, Bitzer M, Siegel D, Ross D, Schulz WA, Zotz RB, Kiel S, Geddert H, Kandemir Y, Walter A, Willers R, Gabbert HE. Association between NAD(P)H: quinone oxidoreductase 1 (NQ01) inactivating C609T polymorphism and adenocarcinoma of the upper gastrointestinal tract. Int J Cancer. 2003 Nov 10; 107(3):381-6.
    View in: PubMed
    Score: 0.018
  66. Zhang J, Schulz WA, Li Y, Wang R, Zotz R, Wen D, Siegel D, Ross D, Gabbert HE, Sarbia M. Association of NAD(P)H: quinone oxidoreductase 1 (NQO1) C609T polymorphism with esophageal squamous cell carcinoma in a German Caucasian and a northern Chinese population. Carcinogenesis. 2003 May; 24(5):905-9.
    View in: PubMed
    Score: 0.018
  67. Gustafson DL, Siegel D, Rastatter JC, Merz AL, Parpal JC, Kepa JK, Ross D, Long ME. Kinetics of NAD(P)H:quinone oxidoreductase I (NQO1) inhibition by mitomycin C in vitro and in vivo. J Pharmacol Exp Ther. 2003 Jun; 305(3):1079-86.
    View in: PubMed
    Score: 0.018
  68. Beall HD, Winski S, Swann E, Hudnott AR, Cotterill AS, O'Sullivan N, Green SJ, Bien R, Siegel D, Ross D, Moody CJ. Indolequinone antitumor agents: correlation between quinone structure, rate of metabolism by recombinant human NAD(P)H:quinone oxidoreductase, and in vitro cytotoxicity. J Med Chem. 1998 Nov 19; 41(24):4755-66.
    View in: PubMed
    Score: 0.013
  69. Beall HD, Hudnott AR, Winski S, Siegel D, Swann E, Ross D, Moody CJ. Indolequinone antitumor agents: relationship between quinone structure and rate of metabolism by recombinant human NQO1. Bioorg Med Chem Lett. 1998 Mar 03; 8(5):545-8.
    View in: PubMed
    Score: 0.012
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2021 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)